{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:41:44Z","timestamp":1786372904434,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.2215\/cjn.01410210","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T21:11:58Z","timestamp":1273180318000},"page":"1132-1140","source":"Crossref","is-referenced-by-count":87,"title":["Aldosterone"],"prefix":"10.2215","volume":"5","author":[{"given":"Robert W.","family":"Schrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwaleed","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230601","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin Sci"},{"key":"R2-25-20230601","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"R3-25-20230601","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-25-20230601","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R5-25-20230601","first-page":"289","article-title":"Serum aldosterone and protein-binding variables in Yanomama Indians: A no-salt culture as compared to partially acculturated Guyanmi Indians","volume":"3","author":"Nowaczynski","year":"1985","journal-title":"Clin Physiol Biochem"},{"key":"R6-25-20230601","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"R7-25-20230601","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2008020232","article-title":"Aldosterone activates NF-kappaB in the collecting duct","volume":"20","author":"Leroy","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R8-25-20230601","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"R9-25-20230601","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","article-title":"Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology","volume":"104","author":"Wilkinson-Berka","year":"2009","journal-title":"Circ Res"},{"key":"R10-25-20230601","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone \u2018escape\u2019 vs \u2018breakthrough.\u2019","volume":"6","author":"Schrier","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"R11-25-20230601","first-page":"721","article-title":"Peripheral arterial vasodilation hypothesis: Implications for impaired aldosterone escape","volume":"3","author":"Schrier","year":"1991","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R12-25-20230601","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000168356","article-title":"Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention","volume":"11","author":"Hensen","year":"1991","journal-title":"Am J Nephrol"},{"key":"R14-25-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-25-20230601","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"EPHESUS Investigators: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"R16-25-20230601","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCHEARTFAILURE.108.821199","article-title":"Sodium retention in cardiac failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist?","volume":"2","author":"Bansal","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R17-25-20230601","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R18-25-20230601","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1093\/eurheartj\/sui008","article-title":"Reassessing treatment of acute heart failure syndromes: The ADHERE registry","volume":"7","author":"Gheorghiade","year":"2005","journal-title":"Eur Heart J"},{"key":"R19-25-20230601","doi-asserted-by":"crossref","first-page":"21A","DOI":"10.1016\/0002-9149(93)90241-4","article-title":"Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor","volume":"71","author":"van Vliet","year":"1993","journal-title":"Am J Cardiol"},{"key":"R20-25-20230601","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.CIR.32.2.223","article-title":"A method for the detection and quantification of impaired sodium excretion: Results of an oral sodium tolerance test in normal subjects and in patients with heart disease","volume":"32","author":"Braunwald","year":"1965","journal-title":"Circulation"},{"key":"R21-25-20230601","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0016-5085(92)90179-3","article-title":"Vasodilatation and sodium retention in prehepatic portal hypertension","volume":"102","author":"Albillos","year":"1992","journal-title":"Gastroenterology"},{"key":"R22-25-20230601","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/0016-5085(92)90340-5","article-title":"Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension","volume":"102","author":"La Villa","year":"1992","journal-title":"Gastroenterology"},{"key":"R23-25-20230601","first-page":"534","article-title":"Complications of diseases in the alcoholic patient: A controlled trial","volume":"73","author":"Gregory","year":"1977","journal-title":"J Gastroenterol"},{"key":"R24-25-20230601","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000183206","article-title":"Lack of effect of captopril on the sodium retention of the nephrotic syndrome","volume":"37","author":"Brown","year":"1984","journal-title":"Nephron"},{"key":"R25-25-20230601","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000168052","article-title":"Role of aldosterone in the sodium retention of patients with nephrotic syndrome","volume":"10","author":"Shapiro","year":"1990","journal-title":"Am J Nephrol"},{"key":"R26-25-20230601","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Anglo-Scandinavian Cardiac Outcomes Trial Investigators: Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R27-25-20230601","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R28-25-20230601","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.K09E-014","article-title":"Endothelial dysfunction is related to aldosterone excess and raised blood pressure","volume":"56","author":"Tsuchiya","year":"2009","journal-title":"Endocr J"},{"key":"R29-25-20230601","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2006121304","article-title":"Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy","volume":"18","author":"Lindenmeyer","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R30-25-20230601","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jphs.08R02CR","article-title":"Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury","volume":"108","author":"Kiyomoto","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"R31-25-20230601","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"R32-25-20230601","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-25-20230601","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-2008-1073154","article-title":"Adrenocortical dysfunction in obesity and the metabolic syndrome","volume":"40","author":"Krug","year":"2008","journal-title":"Horm Metab Res"},{"key":"R34-25-20230601","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","article-title":"Association of adrenal steroids with hypertension and the metabolic syndrome in blacks","volume":"49","author":"Kidambi","year":"2007","journal-title":"Hypertension"},{"key":"R35-25-20230601","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1507\/endocrj.51.243","article-title":"Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade","volume":"51","author":"Yamashita","year":"2004","journal-title":"Endocr J"},{"key":"R36-25-20230601","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"R37-25-20230601","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R38-25-20230601","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ncpneph1004","article-title":"Renal aspirin: Will all patients with chronic kidney disease one day take spironolactone?","volume":"5","author":"Bomback","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"R39-25-20230601","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201006000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:45Z","timestamp":1786369185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201006000-00025"}},"subtitle":["Role in Edematous Disorders, Hypertension, Chronic Renal Failure, and Metabolic Syndrome"],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01410210","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}